source
- Syndax halts development of Niktimvo after Phase 2 failure in IPF trialSyndax announced it is stopping work on its experimental drug Niktimvo for idiopathic pulmonary fibrosis (IPF) after the compound did not meet its primary endpoints in a placebo-controlled Phase 2…
- Nurix halts development of BTK degrader zelebrudomide after phase 1 reviewNurix announced it will discontinue clinical development of its BTK degrader zelebrudomide, also known as NX-2127, following completion of enrollment in a phase 1 trial for aggressive non‑Hodgkin l…